New development of biomarkers for gastrointestinal cancers: From neoplastic cells to tumor microenvironment

Jiajia Zhang, Shafat Quadri, Christopher Wolfgang, Lei Zheng

Research output: Contribution to journalReview article

Abstract

Biomarkers refer to a plethora of biological characteristics that can be quantified to facilitate cancer diagnosis, forecast the prognosis of disease, and predict a response to treatment. The identification of objective biomarkers is among the most crucial steps in the realization of individualized cancer care. Several tumor biomarkers for gastrointestinal malignancies have been applied in the clinical setting to help differentiate between cancer and other conditions, facilitate patient selection for targeted therapies, and to monitor treatment response and recurrence. With the coming of the immunotherapy age, the need for a new development of biomarkers that are indicative of the immune response to tumors are unprecedentedly urgent. Biomarkers from the tumor microenvironment, tumor genome, and signatures from liquid biopsies have been explored, but the majority have shown a limited prognostic or predictive value as single biomarkers. Nevertheless, use of multiplex biomarkers has the potential to provide a significantly increased diagnostic accuracy compared to traditional single biomarker. A comprehensive analysis of immune-biomarkers is needed to reveal the dynamic and multifaceted anti-tumor immunity and thus imply for the rational design of assays and combinational strategies.

Original languageEnglish (US)
Article number87
JournalBiomedicines
Volume6
Issue number3
DOIs
StatePublished - Aug 1 2018

Fingerprint

Gastrointestinal Neoplasms
Tumor Microenvironment
Biomarkers
Tumors
Neoplasms
Tumor Biomarkers
Biopsy
Assays
Immunotherapy
Patient Selection
Genes
Immunity
Therapeutics
Genome
Recurrence
Liquids

Keywords

  • Biomarker
  • Gastrointestinal malignancies
  • Immunotherapy

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

New development of biomarkers for gastrointestinal cancers : From neoplastic cells to tumor microenvironment. / Zhang, Jiajia; Quadri, Shafat; Wolfgang, Christopher; Zheng, Lei.

In: Biomedicines, Vol. 6, No. 3, 87, 01.08.2018.

Research output: Contribution to journalReview article

@article{29dd40d3b43e49fdba448ab39bd0517f,
title = "New development of biomarkers for gastrointestinal cancers: From neoplastic cells to tumor microenvironment",
abstract = "Biomarkers refer to a plethora of biological characteristics that can be quantified to facilitate cancer diagnosis, forecast the prognosis of disease, and predict a response to treatment. The identification of objective biomarkers is among the most crucial steps in the realization of individualized cancer care. Several tumor biomarkers for gastrointestinal malignancies have been applied in the clinical setting to help differentiate between cancer and other conditions, facilitate patient selection for targeted therapies, and to monitor treatment response and recurrence. With the coming of the immunotherapy age, the need for a new development of biomarkers that are indicative of the immune response to tumors are unprecedentedly urgent. Biomarkers from the tumor microenvironment, tumor genome, and signatures from liquid biopsies have been explored, but the majority have shown a limited prognostic or predictive value as single biomarkers. Nevertheless, use of multiplex biomarkers has the potential to provide a significantly increased diagnostic accuracy compared to traditional single biomarker. A comprehensive analysis of immune-biomarkers is needed to reveal the dynamic and multifaceted anti-tumor immunity and thus imply for the rational design of assays and combinational strategies.",
keywords = "Biomarker, Gastrointestinal malignancies, Immunotherapy",
author = "Jiajia Zhang and Shafat Quadri and Christopher Wolfgang and Lei Zheng",
year = "2018",
month = "8",
day = "1",
doi = "10.3390/biomedicines6030087",
language = "English (US)",
volume = "6",
journal = "Biomedicines",
issn = "2227-9059",
publisher = "MDPI AG",
number = "3",

}

TY - JOUR

T1 - New development of biomarkers for gastrointestinal cancers

T2 - From neoplastic cells to tumor microenvironment

AU - Zhang, Jiajia

AU - Quadri, Shafat

AU - Wolfgang, Christopher

AU - Zheng, Lei

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Biomarkers refer to a plethora of biological characteristics that can be quantified to facilitate cancer diagnosis, forecast the prognosis of disease, and predict a response to treatment. The identification of objective biomarkers is among the most crucial steps in the realization of individualized cancer care. Several tumor biomarkers for gastrointestinal malignancies have been applied in the clinical setting to help differentiate between cancer and other conditions, facilitate patient selection for targeted therapies, and to monitor treatment response and recurrence. With the coming of the immunotherapy age, the need for a new development of biomarkers that are indicative of the immune response to tumors are unprecedentedly urgent. Biomarkers from the tumor microenvironment, tumor genome, and signatures from liquid biopsies have been explored, but the majority have shown a limited prognostic or predictive value as single biomarkers. Nevertheless, use of multiplex biomarkers has the potential to provide a significantly increased diagnostic accuracy compared to traditional single biomarker. A comprehensive analysis of immune-biomarkers is needed to reveal the dynamic and multifaceted anti-tumor immunity and thus imply for the rational design of assays and combinational strategies.

AB - Biomarkers refer to a plethora of biological characteristics that can be quantified to facilitate cancer diagnosis, forecast the prognosis of disease, and predict a response to treatment. The identification of objective biomarkers is among the most crucial steps in the realization of individualized cancer care. Several tumor biomarkers for gastrointestinal malignancies have been applied in the clinical setting to help differentiate between cancer and other conditions, facilitate patient selection for targeted therapies, and to monitor treatment response and recurrence. With the coming of the immunotherapy age, the need for a new development of biomarkers that are indicative of the immune response to tumors are unprecedentedly urgent. Biomarkers from the tumor microenvironment, tumor genome, and signatures from liquid biopsies have been explored, but the majority have shown a limited prognostic or predictive value as single biomarkers. Nevertheless, use of multiplex biomarkers has the potential to provide a significantly increased diagnostic accuracy compared to traditional single biomarker. A comprehensive analysis of immune-biomarkers is needed to reveal the dynamic and multifaceted anti-tumor immunity and thus imply for the rational design of assays and combinational strategies.

KW - Biomarker

KW - Gastrointestinal malignancies

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85054497267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054497267&partnerID=8YFLogxK

U2 - 10.3390/biomedicines6030087

DO - 10.3390/biomedicines6030087

M3 - Review article

C2 - 30104497

AN - SCOPUS:85054497267

VL - 6

JO - Biomedicines

JF - Biomedicines

SN - 2227-9059

IS - 3

M1 - 87

ER -